According to a recent LinkedIn post from HistoSonics, company scientific co‑founder Dr. Zhen Xu has been named to TIME’s 2026 TIME100 Health list of influential health leaders. The post highlights her role as co‑inventor of histotripsy and notes that this non‑invasive procedure has already been used in thousands of liver tumor cases, emphasizing the absence of incisions and radiation toxicity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post underscores that Dr. Xu is a University of Michigan engineering professor whose research formed the scientific basis for histotripsy. It also cites her ongoing work to extend the technology’s potential use beyond liver tumors to additional tumor types, neurological diseases, and cardiovascular indications.
For investors, the recognition by TIME suggests growing visibility for HistoSonics’ core technology within the broader medical and scientific community. Increased awareness of histotripsy could support physician adoption, facilitate clinical partnerships, and strengthen the company’s positioning as a developer of non‑invasive therapeutic solutions.
The post also implies a long‑term innovation pipeline anchored in academic collaboration, as Dr. Xu’s team continues to pursue new applications. If these research efforts translate into additional clinical indications, HistoSonics could see an expansion of its addressable market and potential diversification of revenue streams over time.